SEC Tracker
Get the app
FTH · XBRL financial data

Faeth Therapeutics financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (FTH's year ends in late December)

In thousands of dollarsDec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026†Jun 30, 2026Sep 30, 2026
General and administrative3,649*3,8133,2033,1862,834*3,5492,6732,3152,791*19,7139,20510,350
Total operating expenses8,142*8,7307,7877,8238,274*7,2745,2064,8514,957*170,62718,38522,086
Operating income (loss)(8,142)*(8,730)(7,787)(7,823)(8,274)*(7,274)(5,206)(4,851)(4,957)*(170,627)(18,385)(22,086)
Interest expense31*28242117*131063*———
Other income (expense)(67)*(2)00(1)*(2)(1)0(1)*(1)120(88)
Income tax expense (benefit)—00*0*0*0000*000
Net income (loss)(7,414)*(7,992)(7,142)(7,253)(7,770)*(6,864)(4,936)(4,569)(4,717)*(170,236)(16,007)(20,398)
Earnings per share, basic‡ USD per share(6.00)*(6.40)(5.60)(5.80)(6.20)*(5.40)(3.91)(3.62)(3.74)*(131.45)(2.84)(0.79)
Earnings per share, diluted‡ USD per share(6.00)*(6.40)(5.60)(5.80)(6.20)*(5.40)(3.91)(3.62)(3.74)*(131.45)(2.84)(0.79)
Weighted average shares, basic‡ thousands of shares1,251*1,2521,2551,2571,258*1,2601,2611,2611,261*1,2955,64325,841
Weighted average shares, diluted‡ thousands of shares1,251*1,2521,2551,2571,258*1,2601,2611,2611,261*1,2955,64325,841
  • ‡ Per-share figures and share counts are adjusted for the 1-for-20 stock split (June 2025); filings made before it reported them unadjusted.
  • † Share count changed about 19x in the period ending 2026-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Balance sheet

CSV

Fiscal quarters (FTH's year ends in late December)

In thousands of dollarsDec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026†Jun 30, 2026Sep 30, 2026
Cash and cash equivalents13,01110,95611,89119,1319,9949,87712,55710,5628,668152,32526,90314,180
Marketable securities52,74647,12540,39827,87031,34124,45416,07114,47912,51650,468159,538160,615
Total current assets67,25060,23453,94448,09841,92935,68229,57225,78521,507204,232188,658177,841
Property and equipment, net1,1651,0651,0388994171591431128269441
Right-of-use asset4,3303,9603,5733,2062,8042,3932,0341,6681,294913524126
Goodwill—————————000
Total assets74,37466,69559,79953,25445,36138,27331,78327,58922,902205,381189,306178,949
Accounts payable573———2443613513066893,4182,1472,988
Accrued liabilities900———8471,9097041,0197155,4285,2515,419
Total current liabilities5,6434,9924,9495,4415,4485,2293,8734,4364,25114,1909,58011,032
Lease liability, non-current3,0012,5902,2141,8281,4291,0225921465900—
Total liabilities9,4798,2217,6077,4756,9756,2864,4694,5824,31014,1919,58111,085
Accumulated deficit(231,895)(239,887)(247,029)(254,282)(262,052)(268,916)(273,852)(278,421)(283,137)(453,373)(469,380)(489,778)
Total stockholders' equity64,89558,47452,19245,77938,38631,98727,31423,00718,592(137,286)172,958161,097
Total liabilities and equity74,37466,69559,79953,25445,36138,27331,78327,58922,902205,381189,306178,949
Common shares outstanding (cover page)‡ thousands of shares1,2541,2541,2581,2581,2601,2601,2611,2611,3401,34225,84025,844
  • ‡ Per-share figures and share counts are adjusted for the 1-for-20 stock split (June 2025); filings made before it reported them unadjusted.
  • † Share count changed about 19x in the period ending 2026-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Cash flows

CSV

Fiscal quarters (FTH's year ends in late December)

In thousands of dollarsDec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026†Jun 30, 2026Sep 30, 2026
Net income (loss)(7,414)*(7,992)(7,142)(7,253)(7,770)*(6,864)(4,936)(4,569)(4,717)*(170,236)(16,007)(20,398)
Stock-based compensation1,098*1,216795*733*391*461264*254*295*12,8984,483*8,522*
Depreciation and amortization135*137135140139*3032*30*30*2925*17*
Net cash from operating activities(6,163)*(7,616)(5,792)*(5,470)*(5,792)*(7,094)(5,909)*(3,586)*(3,864)*(10,733)(15,673)*(13,002)*
Purchases of property and equipment0*37109*0*0*016*0*0*60*3*
Net cash from investing activities8,262*5,7706,907*12,914*(3,151)*7,1918,757*1,743*2,081*(31,436)(108,066)*175*
Share repurchases252*———————————
Net cash from financing activities(431)*(209)(180)*(204)*(194)*(214)(168)*(152)*(111)*185,826(1,683)*104*
Net change in cash1,668*(2,055)935*7,240*(9,137)*(117)2,680*(1,995)*(1,894)*143,657(125,422)*(12,723)*
  • † Share count changed about 19x in the period ending 2026-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Compare with peers

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
  • A cell reading “not reported” means the filings give no figure for that quarter alone.
  • A cell reading “year only” links to a 10-K that gives only the full year: without all three earlier quarters there is no fourth quarter to work out, and the year total is never shown as a quarter.
CompanyCash ($K)Revenue, quarter ($K)Operating cash flow, quarter ($K)Shares outstandingRunwayQuarter
Faeth Therapeutics14,180not reported(13,002)*25.8M13.3 quarters 10-QSep 30, 2026
Zeo ScientifiX2,265not reportednot reported7.8M— 10-KTJun 30, 2026
Sunshine Biopharma13,7489,264(918)*3.9M15.0 quarters 10-QJun 30, 2026
Neuphoria Therapeutics19,866year only1,214*5.4M— 10-KJun 30, 2026
CV Sciences2662,98520*225.8M— 10-QJun 30, 2026
Minerva Neurosciences24,652not reported(13,345)*47.7M5.6 quarters 10-QJun 30, 2026
Bolt Biotherapeutics12,8605(6,540)*1.9M2.7 quarters 10-QJun 30, 2026
Intensity Therapeutics8,494not reported(2,500)*3.3M3.8 quarters 10-QSep 30, 2026
Genprex15,154not reported(5,139)*819,7092.9 quarters 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.

Data on this page was fetched . The filing on SEC.gov is the record.